GSK PLC Sponsored ADR (NYSE:GSK) Stock Has Consensus Price Target of $56.30 According to Brokerages

Key Points

• Analyst consensus is “Hold”: Of 19 firms covering GSK, 13 rate it Hold, while three recommend Buy and three Sell. The average 12-month price target is $56.30.
• GSK shares opened at $50.49, within a 52-week range of $45.81–$61.69.
• GSK raised its quarterly dividend slightly to $0.4518 per share, equivalent to about $1.81 annually and a 3.6% yield.

Shares of GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) have been given an average rating of "Hold" by the nineteen research firms that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, thirteen have issued a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $56.30.

GSK has been the subject of a number of recent research reports. Wall Street Zen cut GSK from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Deutsche Bank reaffirmed a "neutral" rating on shares of GSK in a research note on Tuesday, September 29th. Citigroup initiated coverage on shares of GSK in a research report on Friday, July 24th. They issued a "neutral" rating on the stock. Royal Bank Of Canada initiated coverage on GSK in a research report on Tuesday, September 8th. They set a "sector perform" rating for the company. Finally, Barclays reaffirmed a "sell" rating on shares of GSK in a research note on Monday, September 7th.

GSK Trading Down 0.3%

Shares of GSK opened at $50.49 on Friday. The stock has a market capitalization of $102.13 billion, a PE ratio of 17.54, a P/E/G ratio of 2.28 and a beta of 0.29. The company's fifty day moving average is $49.30 and its 200 day moving average is $52.40. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.56 and a current ratio of 0.86. GSK has a fifty-two week low of $45.81 and a fifty-two week high of $61.69.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, January 7th. Investors of record on Friday, November 13th will be issued a dividend of $0.4518 per share. This represents a $1.81 dividend on an annualized basis and a yield of 3.6%. The ex-dividend date is Friday, November 13th. This is an increase from GSK's previous quarterly dividend of $0.4515. GSK's dividend payout ratio (DPR) is presently 61.46%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Security National Bank of SO Dak bought a new stake in shares of GSK during the second quarter valued at approximately $38,000. Laurel Wealth Advisors LLC bought a new position in shares of GSK during the 3rd quarter worth $36,000. Trust Co. of Vermont bought a new position in shares of GSK during the 2nd quarter worth $54,000. Provenance Wealth Advisors LLC grew its position in shares of GSK by 378.8% during the 3rd quarter. Provenance Wealth Advisors LLC now owns 1,149 shares of the pharmaceutical company's stock worth $55,000 after buying an additional 909 shares in the last quarter. Finally, Philadelphia Investment Partners LLC bought a new stake in shares of GSK in the second quarter valued at about $70,000. 15.74% of the stock is currently owned by institutional investors.

About GSK

GSK plc is a global biopharmaceutical company headquartered in the United Kingdom. It researches, develops and manufactures medicines and vaccines, with a focus on areas including infectious diseases, HIV, respiratory and immune conditions, and cancer. Its products include vaccines such as Shingrix, which helps prevent shingles, and Arexvy, for respiratory syncytial virus (RSV). GSK also makes specialty medicines, including treatments for HIV and respiratory diseases, and continues to develop new medicines and vaccines through its research programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.